Funding for this research was provided by:
Lupin Pharmaceuticals
Article History
Received: 30 August 2022
Accepted: 18 January 2024
First Online: 28 February 2024
Declarations
:
: Andrew Lloyd is an employee and stock holder in Acaster Lloyd Consulting Ltd which was paid a fixed fee by Lupin Healthcare (UK) Limited for work on this project. Kim Rand is an employee and stock holder in Maths in Health which was paid a fixed fee by Lupin Healthcare (UK) Limited for work on this project. Cleo Pike is a freelance contractor paid for her time on the project. Crispin Ellis is an employee and stock holder in Lupin Pharmaceuticals who market Mexiletine for the treatment of non-dystrophic myotonia. The authors declare no other competing interests.